Cita APA

Modi, S., Krop, I., Kim, S., Tamura, K., Saura Manich, C., & Park, Y. H. (2024). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01).

Citación estilo Chicago

Modi, Shanu, Ian Krop, Sung‑Bae Kim, K. Tamura, Cristina Saura Manich, y Yeon Hee Park. Trastuzumab Deruxtecan in Previously Treated Patients With HER2-positive Metastatic Breast Cancer: Updated Survival Results From a Phase II Trial (DESTINY-Breast01). 2024.

Cita MLA

Modi, Shanu, et al. Trastuzumab Deruxtecan in Previously Treated Patients With HER2-positive Metastatic Breast Cancer: Updated Survival Results From a Phase II Trial (DESTINY-Breast01). 2024.